Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.AIDS Community Research Initiative of America (ACRIA) - Fall 2004
Tipranavir Open Label Safety Study
People whose virus has become resistant to approved HIV treatments or who are intolerant to them will take tipranavir with Norvir, along with other anti-HIV drugs, for an open period of time. Participants should be 13 years of age or older, have a viral load above 10,000 and a CD4 count below 100 to enroll in this program.
UK-427,857 for Drug-Resistant HIV
People who have taken anti-HIV drugs from three of the four classes of drugs will take either UK-427 (an experimental HIV attachment inhibitor) with an optimized regimen of anti-HIV drugs, or take a placebo (dummy pill) with the optimized regimen, for 11 months. Participants must be 16 or older and have a viral load of at least 5,000.
The Effect of Reyataz on Cholesterol Levels
People who have high cholesterol levels and a viral load below 50 while taking Kaletra will either switch to Reyataz or continue taking Kaletra. The study will last 12 months. Study participants will be reimbursed $25 for each visit.
Reyataz Compared to Kaletra
People whose viral load has risen to over 1,000 while taking an NNRTI as part of their first HAART regimen will switch to either Kaletra, or to Reyataz / Norvir. Everyone will also take Viread and either Videx EC or Zerit XR. The study will last for 22 months. Study participants will be reimbursed $25 for each visit.
One-day study of Reyataz Resistance
People whose viral load has risen to over 1,000 while taking Reyataz will have blood tests for resistance, CD4, and viral load. Study participants will be reimbursed $25.
Phase I Study of a New GlaxoSmithKline NNRTI
People who have become resistant to an NNRTI and who have a CD4 count over 200 and a viral load over 2,000 will take one of four doses of W695634G alone, or take placebo pills, for 7 days. Those who complete the study will be reimbursed $590.
For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.
Standard of Care Treatment vs. ZEST Once-Daily Regimen
(Closed to Enrollment) This trial is studying whether people on their first HAART regimen who take their drugs two or more times a day can switch to a once-daily regimen. People in the trial either remain on their current medications, or switch to Zerit XR, Epivir and Sustiva (ZEST) taken once daily.
20041001
CR041001
Copyright © 2004 - AIDS Community Research Initiative of America. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, ACRIA Update, 230 West 38th Street, 17th Floor, New York, NY 10018; (212) 924-3934; Fax (212) 924-3936 .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, the National Library of Medicine, Bridgestone Firestone Trust Fund and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. ÆGIS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.